Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2020-12-11 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于授权公司经营管理层启动分拆子公司境内上市前期筹备工作的提示性公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the authorization for the company's management to initiate preparatory work for the spin-off and domestic listing of its wholly-owned subsidiary, Shenzhen Xinlitai Biomedical Engineering Co., Ltd. It details the board meeting resolution, basic information about the subsidiary, authorization scope, independent directors' opinions, and risk warnings. The document is a preparatory announcement about a potential capital market transaction (spin-off and listing) but does not contain financial statements, earnings data, or detailed financial analysis. It is not a full report but an official notice about the company's financing and capital structure plans. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short (1749 characters), and it is not merely a report publication announcement or regulatory filing. Hence, the classification is CAP with high confidence.
2020-12-11 Chinese
2020年度非公开发行A股股票预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed plan and proposal for a non-public issuance of A shares by Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes extensive information about the issuance background, purpose, pricing, number of shares, use of proceeds, approval procedures, and related financial and operational impacts. The document is titled as a "2020年度非公开发行A股股票预案（修订稿）" which translates to "2020 Annual Non-public Issuance of A Shares Proposal (Revised Draft)". It is a comprehensive disclosure related to capital raising through a share issuance, including detailed financial and strategic information about the use of funds and the impact on the company. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. It is not an announcement of a report publication, nor a full annual or interim report, nor a regulatory filing or other categories. The document length and detail confirm it is the actual proposal document, not just an announcement or summary. Therefore, the correct classification is CAP with high confidence.
2020-12-11 Chinese
关于非公开发行A股股票预案修订说明的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the revision of a non-public issuance plan of A shares by Shenzhen Salubris Pharmaceuticals Co., Ltd. It details updates to the issuance plan, including fundraising amounts, project investment, risk disclosures, and approval procedures. The document is relatively short (1447 characters) and serves as a public notice of changes to a capital raising plan rather than the full detailed plan or financial report itself. It does not contain actual financial statements or comprehensive financial data but rather updates and disclosures related to a capital issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2020-12-11 Chinese
独立董事关于公司有关事项所发表的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of Shenzhen Xinlitai Pharmaceutical Co., Ltd. It discusses their review and approval of specific company matters such as the adjustment of a 2020 non-public issuance of A shares, goodwill impairment provision, and authorization to start preparatory work for a subsidiary's domestic listing. The document references compliance with company law, securities regulations, and company articles, and it is signed by the independent directors. The content is focused on governance and compliance opinions rather than financial results, audit opinions, or detailed financial data. It is not a full annual report, audit report, or earnings release. It is also not a simple announcement or certification but a formal governance-related opinion document. Therefore, the best fitting category is Board/Management Information (MANG), as it relates to board-level opinions on company matters and approvals.
2020-12-11 Chinese
独立董事关于公司有关事项的事前认可意见
Capital/Financing Update Classification · 90% confidence The document is a statement from independent directors providing prior approval opinions on a proposed adjustment to a non-public issuance of A shares for the year 2020. It references compliance with company law, securities law, and regulatory requirements from the China Securities Regulatory Commission and the Shenzhen Stock Exchange. The document is short (1217 characters) and primarily contains the independent directors' opinions and approvals regarding a capital raising proposal. It does not contain financial statements, detailed financial data, or a full report. It is not a full capital/financing update report but rather an official opinion or approval related to a financing activity. Given the nature of the document as an official approval related to a financing proposal, the best fitting category is Capital/Financing Update (CAP).
2020-12-11 Chinese
关于计提商誉减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the provision for goodwill impairment. It details the decision made by the board of directors to recognize a goodwill impairment loss of 282.72 million yuan related to its subsidiary Suzhou Huancheng Medical Technology Co., Ltd. The document includes explanations of the goodwill formation, impairment testing, approval procedures, and opinions from the audit committee, board, independent directors, and supervisory board. It is a formal announcement of a specific accounting event (goodwill impairment) rather than a full financial report or audit report. The document length is 3390 characters, which is relatively short and focused on a single event. It does not contain comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It is not a certification or officer attestation, so it is not Regulatory Filings (RNS). It is not a report publication announcement since it contains substantive content about the impairment decision and its rationale. Therefore, the document best fits the category of a Regulatory Filing (RNS) as a formal disclosure of a significant accounting event that does not fit other specific categories like Annual Report or Audit Report.
2020-12-11 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.